Rett Syndrome: A Timely Review From Recognition to Current Clinical Approaches and Clinical Study Updates

Rett, 1966, [On an unusual brain atrophy syndrome in hyperammonemia in childhood], Wien Med Wochenschr, 116, 723 Hagberg, 1983, A progressive syndrome of autism, dementia, ataxia, and loss of purposeful hand use in girls: Rett's syndrome: Report of 35 cases, Ann Neurol, 14, 471, 10.1002/ana.410140412 Amir, 1999, Rett syndrome is caused by mutations in X-linked MECP2, encoding methylCpG-binding protein 2, Nat Genet, 23, 185, 10.1038/13810 Chahrour, 2007, The story of Rett syndrome: From clinic to neurobiology, Neuron, 56, 422, 10.1016/j.neuron.2007.10.001 Sandweiss, 2020, Advances in understanding of Rett syndrome and MECP2 duplication syndrome: Prospects for future therapies, The Lancet. Neurology, 19, 689, 10.1016/S1474-4422(20)30217-9 Kaur, S. & J. Christodoulou, MECP2 disorders. In: GeneReviews(®)Adam MP, Ardinger HH, Pagon RA, et al, eds. GeneReviews, University of Washington; 1993-2020. Guy, 2011, The role of MeCP2 in the brain, Annu Rev Cell Dev Biol, 27, 631, 10.1146/annurev-cellbio-092910-154121 Lewis, 1992, Purification, sequence, and cellular localization of a novel chromosomal protein that binds to methylated DNA, Cell, 69, 905, 10.1016/0092-8674(92)90610-O Nan, 1997, MeCP2 is a transcriptional repressor with abundant binding sites in genomic chromatin, Cell, 88, 471, 10.1016/S0092-8674(00)81887-5 Chahrour, 2008, MeCP2, a key contributor to neurological disease, activates and represses transcription, Science, 320, 1224, 10.1126/science.1153252 Jones, 2012, Functions of DNA methylation: Islands, start sites, gene bodies and beyond, Nat Rev Genet, 13 Krishnaraj, 2017, RettBASE: Rett syndrome database update, Hum Mutat, 38, 922, 10.1002/humu.23263 Guo, 2014, Distribution, recognition and regulation of non-CpG methylation in the adult mammalian brain, Nat Neurosci, 17, 215, 10.1038/nn.3607 Lister, 2013, Global epigenomic reconfiguration during mammalian brain development, Science (New York, N.Y.), 341, 10.1126/science.1237905 Shahbazian, 2002, Insight into Rett syndrome: MeCP2 levels display tissue- and cell-specific differences and correlate with neuronal maturation, Hum Mol Genet, 11, 115, 10.1093/hmg/11.2.115 Chen, 2015, MeCP2 binds to non-CG methylated DNA as neurons mature, influencing transcription and the timing of onset for Rett syndrome, Proc Natl Acad Sci U S A, 112 Lavery, 2019, The distinct methylation landscape of maturing neurons and its role in Rett syndrome pathogenesis, Curr Opin Neurobiol, 59, 180, 10.1016/j.conb.2019.08.001 Baker, 2013, An AT-hook domain in MeCP2 determines the clinical course of Rett syndrome and related disorders, Cell, 152, 984, 10.1016/j.cell.2013.01.038 Connolly, 2019, Genomic insights into MeCP2 function: A role for the maintenance of chromatin architecture, Curr Opin Neurobiol, 59, 174, 10.1016/j.conb.2019.07.002 Bellini, 2014, MeCP2 post-translational modifications: A mechanism to control its involvement in synaptic plasticity and homeostasis?, Front Cell Neurosci, 8, 236, 10.3389/fncel.2014.00236 Guy, 2001, A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome, Nat Genet, 27, 322, 10.1038/85899 Chen, 2001, Deficiency of methyl-CpG binding protein-2 in CNS neurons results in a Rett-like phenotype in mice, Nat Genet, 27, 327, 10.1038/85906 Fukuda, 2005, Delayed maturation of neuronal architecture and synaptogenesis in cerebral cortex of Mecp2-deficient mice, J Neuropathol Exp Neurol, 64, 537, 10.1093/jnen/64.6.537 Chapleau, 2009, Dendritic spine pathologies in hippocampal pyramidal neurons from Rett syndrome brain and after expression of Rett-associated MECP2 mutations, Neurobiol Dis, 35, 219, 10.1016/j.nbd.2009.05.001 Marchetto, 2010, A model for neural development and treatment of Rett syndrome using human induced pluripotent stem cells, Cell, 143, 527, 10.1016/j.cell.2010.10.016 Asaka, 2006, Hippocampal synaptic plasticity is impaired in the Mecp2-null mouse model of Rett syndrome, Neurobiol Dis, 21, 217, 10.1016/j.nbd.2005.07.005 El-Khoury, 2014, GABA and glutamate pathways are spatially and developmentally affected in the brain of Mecp2-deficient mice, PLoS One, 9, e92169, 10.1371/journal.pone.0092169 McGraw, 2011, Adult neural function requires MeCP2, Science (New York, N.Y.), 333, 186, 10.1126/science.1206593 Guy, 2007, Reversal of neurological defects in a mouse model of Rett syndrome, Science (New York, N.Y.), 315, 1143, 10.1126/science.1138389 Robinson, 2012, Morphological and functional reversal of phenotypes in a mouse model of Rett syndrome, Brain, 135, 2699, 10.1093/brain/aws096 Ross, 2016, Exclusive expression of MeCP2 in the nervous system distinguishes between brain and peripheral Rett syndrome-like phenotypes, Hum Mol Genet, 25, 4389 Caballero, 2005, MeCP2 in neurons: closing in on the causes of Rett syndrome, Hum Mol Genet, 14, R19, 10.1093/hmg/ddi102 Neul, 2008, Specific mutations in methyl-CpG-binding protein 2 confer different severity in Rett syndrome, Neurology, 70, 1313, 10.1212/01.wnl.0000291011.54508.aa Bebbington, 2010, Updating the profile of C-terminal MECP2 deletions in Rett syndrome, J Med Genet, 47, 242, 10.1136/jmg.2009.072553 Cuddapah, 2014, Methyl-CpG-binding protein 2 (MECP2) mutation type is associated with disease severity in Rett syndrome, J Med Genet, 51, 152, 10.1136/jmedgenet-2013-102113 Archer, 2007, Correlation between clinical severity in patients with Rett syndrome with a p.R168X or p.T158M MECP2 mutation, and the direction and degree of skewing of X chromosome inactivation, J Med Genet, 44, 148, 10.1136/jmg.2006.045260 Tarquinio, 2017, Longitudinal course of epilepsy in Rett syndrome and related disorders, Brain, 140, 306, 10.1093/brain/aww302 Tarquinio, 2018, The course of awake breathing disturbances across the lifespan in Rett syndrome, Brain Dev, 40, 515, 10.1016/j.braindev.2018.03.010 Lombardi, 2015, MECP2 disorders: From the clinic to mice and back, J Clin Invest, 125, 2914, 10.1172/JCI78167 Armstrong, 2005, Neuropathology of Rett syndrome, J Child Neurol, 20, 747, 10.1177/08830738050200082401 Kron, 2012, Brain activity mapping in Mecp2 mutant mice reveals functional deficits in forebrain circuits, including key nodes in the default mode network, that are reversed with ketamine treatment, J Neurosci, 32, 13860, 10.1523/JNEUROSCI.2159-12.2012 Shepherd, 2011, Synaptic microcircuit dysfunction in genetic models of neurodevelopmental disorders: Focus on Mecp2 and Met, Curr Opin Neurobiol, 21, 827, 10.1016/j.conb.2011.06.006 Zhang, 2008, The MeCP2-null mouse hippocampus displays altered basal inhibitory rhythms and is prone to hyperexcitability, Hippocampus, 18, 294, 10.1002/hipo.20389 Wood, 2010, Synaptic circuit abnormalities of motor-frontal layer 2/3 pyramidal neurons in a mutant mouse model of Rett syndrome, Neurobiol Dis, 38, 281, 10.1016/j.nbd.2010.01.018 Dani, 2009, Intact long-term potentiation but reduced connectivity between neocortical layer 5 pyramidal neurons in a mouse model of Rett syndrome, J Neurosci, 29, 10.1523/JNEUROSCI.1019-09.2009 Maezawa, 2010, Rett syndrome microglia damage dendrites and synapses by the elevated release of glutamate, J Neurosci, 30, 5346, 10.1523/JNEUROSCI.5966-09.2010 Maezawa, 2009, Rett syndrome astrocytes are abnormal and spread MeCP2 deficiency through gap junctions, J Neurosci, 29, 5051, 10.1523/JNEUROSCI.0324-09.2009 Nguyen, 2013, Oligodendrocyte lineage cells contribute unique features to Rett syndrome neuropathology, J Neurosci, 33, 18764, 10.1523/JNEUROSCI.2657-13.2013 Calfa, 2011, Experimental models of Rett syndrome based on Mecp2 dysfunction, Exp Biol Med (Maywood), 236, 3, 10.1258/ebm.2010.010261 Ghosh, 1994, Requirement for BDNF in activity-dependent survival of cortical neurons, Science, 263, 1618, 10.1126/science.7907431 Poo, 2001, Neurotrophins as synaptic modulators, Nat Rev Neurosci, 2, 24, 10.1038/35049004 Chang, 2006, The disease progression of Mecp2 mutant mice is affected by the level of BDNF expression, Neuron, 49, 341, 10.1016/j.neuron.2005.12.027 Larimore, 2009, Bdnf overexpression in hippocampal neurons prevents dendritic atrophy caused by Rett-associated MECP2 mutations, Neurobiol Dis, 34, 199, 10.1016/j.nbd.2008.12.011 Chapleau, 2013, Recent progress in Rett syndrome and MeCP2 dysfunction: Assessment of potential treatment options, Future Neurol, 8, 10.2217/fnl.12.79 Cuddapah, 2015, MeCP2 in the regulation of neural activity: Rett syndrome pathophysiological perspectives, Degener Neurol Neuromuscul Dis, 5, 103 Wenk, 1997, Rett syndrome: Neurobiological changes underlying specific symptoms, Prog Neurobiol, 51, 383, 10.1016/S0301-0082(96)00059-7 Maliszewska-Cyna, 2010, Diminished prevalence but preserved synaptic distribution of N-methyl-D-aspartate receptor subunits in the methyl CpG binding protein 2(MeCP2)-null mouse brain, Neuroscience, 168, 624, 10.1016/j.neuroscience.2010.03.065 Chao, 2010, Dysfunction in GABA signaling mediates autism-like stereotypies and Rett syndrome phenotypes, Nature, 468, 263, 10.1038/nature09582 Meng, 2016, Manipulations of MeCP2 in glutamatergic neurons highlight their contributions to Rett and other neurological disorders, Elife, 5, 10.7554/eLife.14199 Can, 2019, Neuronal redox-imbalance in rett syndrome affects mitochondria as well as cytosol, and is accompanied by intensified mitochondrial O (2) consumption and ROS release, Front Physiol, 10, 479, 10.3389/fphys.2019.00479 Jagtap, 2019, Aberrant mitochondrial function in patient-derived neural cells from CDKL5 deficiency disorder and Rett syndrome, Hum Mol Genet, 28, 3625, 10.1093/hmg/ddz208 Grosser, 2012, Oxidative burden and mitochondrial dysfunction in a mouse model of Rett syndrome, Neurobiol Dis, 48, 102, 10.1016/j.nbd.2012.06.007 Katz, 2016, Rett syndrome: Crossing the threshold to clinical translation, Trends Neurosci, 39, 100, 10.1016/j.tins.2015.12.008 Kaufmann, 2016, Neurobiologically-based treatments in Rett syndrome: Opportunities and challenges, Expert Opin Orphan Drugs, 4 Gomathi, 2020, Drug studies on Rett syndrome: From bench to bedside, J Autism Dev Disord, 50, 2740, 10.1007/s10803-020-04381-y Su, 2016, The sigma-1 receptor as a pluripotent modulator in living systems, Trends Pharmacol Sci, 37, 262, 10.1016/j.tips.2016.01.003 Kaufmann, 2019, ANAVEX®2-73 (blarcamesine), a Sigma-1 receptor agonist, ameliorates neurologic impairments in a mouse model of Rett syndrome, Pharmacol Biochem Behav, 187, 10.1016/j.pbb.2019.172796 Banerjee, 2019, Towards a better diagnosis and treatment of Rett syndrome: A model synaptic disorder, Brain, 142, 239, 10.1093/brain/awy323 Devinsky, 2016, Cannabidiol in patients with treatment-resistant epilepsy - Authors' reply, Lancet Neurol, 15, 545, 10.1016/S1474-4422(16)00120-4 Devinsky, 2016, Cannabidiol in patients with treatment-resistant epilepsy: An open-label interventional trial, Lancet Neurol, 15, 270, 10.1016/S1474-4422(15)00379-8 Ibeas Bih, 2015, Molecular targets of cannabidiol in neurological disorders, Neurotherapeutics, 12, 699, 10.1007/s13311-015-0377-3 Vigli, 2018, Chronic treatment with the phytocannabinoid Cannabidivarin (CBDV) rescues behavioural alterations and brain atrophy in a mouse model of Rett syndrome, Neuropharmacology, 140, 121, 10.1016/j.neuropharm.2018.07.029 Lu, 2009, NNZ-2566, a glypromate analog, attenuates brain ischemia-induced non-convulsive seizures in rats, J Cereb Blood Flow Metab, 29, 1924, 10.1038/jcbfm.2009.109 Wei, 2009, NNZ-2566 treatment inhibits neuroinflammation and pro-inflammatory cytokine expression induced by experimental penetrating ballistic-like brain injury in rats, J Neuroinflammation, 6, 19, 10.1186/1742-2094-6-19 Tropea, 2009, Partial reversal of Rett syndrome-like symptoms in MeCP2 mutant mice, Proc Natl Acad Sci USA, 106, 2029, 10.1073/pnas.0812394106 Glaze, 2019, Double-blind, randomized, placebo-controlled study of trofinetide in pediatric Rett syndrome, Neurology, 92, 1912, 10.1212/WNL.0000000000007316 Patrizi, 2016, Chronic administration of N-Methyl-D-Aspartate receptor antagonist ketamine improves Rett syndrome phenotype, Biol Psychiatry, 79, 755, 10.1016/j.biopsych.2015.08.018 Katz, 2016, N-Methyl-D-Aspartate receptors, ketamine, and Rett syndrome: Something special on the road to treatments?, Biol Psychiatry, 79, 710, 10.1016/j.biopsych.2016.03.1045 Heard, 2004, Recent advances in X-chromosome inactivation, Curr Opin Cell Biol, 16, 247, 10.1016/j.ceb.2004.03.005 Gray, 2011, Preclinical differences of intravascular AAV9 delivery to neurons and glia: A comparative study of adult mice and nonhuman primates, Mol Ther, 19, 1058, 10.1038/mt.2011.72 Giacometti, 2007, Partial rescue of MeCP2 deficiency by postnatal activation of MeCP2, Proc Natl Acad Sci U S A, 104, 1931, 10.1073/pnas.0610593104 Luikenhuis, 2004, Expression of MeCP2 in postmitotic neurons rescues Rett syndrome in mice, Proc Natl Acad Sci U S A, 101, 6033, 10.1073/pnas.0401626101 Derecki, 2012, Wild-type microglia arrest pathology in a mouse model of Rett syndrome, Nature, 484, 105, 10.1038/nature10907 Lioy, 2011, A role for glia in the progression of Rett's syndrome, Nature, 475, 497, 10.1038/nature10214 Keeling, 2014, Therapeutics based on stop codon readthrough, Annu Rev Genomics Hum Genet, 15, 371, 10.1146/annurev-genom-091212-153527 Gadalla, 2013, Improved survival and reduced phenotypic severity following AAV9/MECP2 gene transfer to neonatal and juvenile male Mecp2 knockout mice, Mol Ther, 21, 18, 10.1038/mt.2012.200 Duque, 2009, Intravenous administration of self-complementary AAV9 enables transgene delivery to adult motor neurons, Mol Ther, 17, 1187, 10.1038/mt.2009.71 Fu, 2020, Consensus guidelines on managing Rett syndrome across the lifespan, BMJ Paediatrics Open, 4, 10.1136/bmjpo-2020-000717 Kumandas, 2001, Lamotrigine in two cases of Rett syndrome, Brain Dev, 23, 240, 10.1016/S0387-7604(01)00191-7 Uldall, 1993, Lamotrigine in Rett syndrome, Neuropediatrics, 24, 339, 10.1055/s-2008-1071568 Pintaudi, 2015, Antiepileptic drugs in Rett syndrome, Eur J Paediatr Neurol, 19, 446, 10.1016/j.ejpn.2015.02.007 Goyal, 2004, Effect of topiramate on seizures and respiratory dysrhythmia in Rett syndrome, J Child Neurol, 19, 588, 10.1177/088307380401900804 Krajnc, 2014, Severe respiratory dysrhythmia in Rett syndrome treated with topiramate, J Child Neurol, 29, 10.1177/0883073813508313 Haas, 1986, Therapeutic effects of a ketogenic diet in Rett syndrome, Am J Med Genet Suppl, 1, 225, 10.1002/ajmg.1320250525 Liebhaber, 2003, Ketogenic diet in Rett syndrome, J Child Neurol, 18, 74, 10.1177/08830738030180011801 Mantis, 2009, Improvement in motor and exploratory behavior in Rett syndrome mice with restricted ketogenic and standard diets, Epilepsy Behav, 15, 133, 10.1016/j.yebeh.2009.02.038 Barchel, 2019, Oral cannabidiol use in children with autism spectrum disorder to treat related symptoms and co-morbidities, Front Pharmacol, 9, 10.3389/fphar.2018.01521 Poleg, 2019, Cannabidiol as a suggested candidate for treatment of autism spectrum disorder, Prog Neuropsychopharmacol Biol Psychiatry, 89, 90, 10.1016/j.pnpbp.2018.08.030 Chin, 2019, Behavioral characterization of MeCP2 dysfunction-associated Rett syndrome and neuropsychiatric disorders, Methods Mol Biol, 2011, 593, 10.1007/978-1-4939-9554-7_34 Katz, 2009, Breathing disorders in Rett syndrome: Progressive neurochemical dysfunction in the respiratory network after birth, Respir Physiol Neurobiol, 168, 101, 10.1016/j.resp.2009.04.017 Ramirez, 2013, Breathing challenges in Rett Syndrome: Lessons learned from humans and animal models, Respir Physiol Neurobiol, 189, 280, 10.1016/j.resp.2013.06.022 Barnes, 2015, Anxiety-like behavior in Rett syndrome: Characteristics and assessment by anxiety scales, J Neurodev Disord, 7, 30, 10.1186/s11689-015-9127-4 Buchanan, 2019, Behavioral profiles in Rett syndrome: Data from the natural history study, Brain Dev, 41, 123, 10.1016/j.braindev.2018.08.008 Brücke, 1987, Reduced concentrations and increased metabolism of biogenic amines in a single case of Rett-syndrome: a postmortem brain study, J Neural Transm, 68, 315, 10.1007/BF02098506 Samaco, 2009, Loss of MeCP2 in aminergic neurons causes cell-autonomous defects in neurotransmitter synthesis and specific behavioral abnormalities, Proc Natl Acad Sci U S A, 106, 21966, 10.1073/pnas.0912257106 De Filippis, 2014, Pharmacological stimulation of the brain serotonin receptor 7 as a novel therapeutic approach for Rett syndrome, Neuropsychopharmacology, 39, 2506, 10.1038/npp.2014.105 Toward, 2013, Increasing brain serotonin corrects CO2 chemosensitivity in methyl-CpG-binding protein 2 (Mecp2)-deficient mice, Exp Physiol, 98, 842, 10.1113/expphysiol.2012.069872 Gökben, 2012, Use of buspirone and fluoxetine for breathing problems in Rett syndrome, Pediatr Neurol, 46, 192, 10.1016/j.pediatrneurol.2011.12.003 Ohno K, et al: Effect of serotonin 1A agonists and selective serotonin reuptake inhibitors on behavioral and nighttime respiratory symptoms in Rett syndrome. Pediatric Neurol 60:5459.e51, 2016